Large Simple Neuroprotective Trials in Parkinson's Disease

帕金森病的大型简单神经保护试验

• 批准号: 7561665
• 负责人: Caroline M. Tanner
• 金额: $ 10.17万
• 依托单位: PARKINSON'S INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2012-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7561665
• 关键词: Age; Characteristics; Clinical; Clinical Trials; Conduct Clinical Trials; Confidentiality; Educational Activities; Elderly; Enrollment; Environment; Goals; Institutes; Multicenter Trials; Neurodegenerative Disorders; Neuroprotective Agents; North America; Parkinson Disease; Participant; Physicians; Population; Public Health; Qualifying; Research; Safety; Support Groups; data integrity; experience; patient population; prevent; social; volunteer

DESCRIPTION (provided by applicant): The goal of this clinical center application is to describe the qualifications of the Parkinson's Institute as a participant in the large simple trial of neuroprotective therapy for Parkinson's disease as proposed in RFA NS-02-010. The Parkinson's Institute has a supportive research environment, extensive clinical trials experience and highly qualified staff, together with experience in the recruitment of clinical trials volunteers and an excellent relationship with support groups. Institute staff have more than 80 years of combined experience in clinical trials, primarily investigating therapies for Parkinson's disease. The Parkinson's Institute has considerable experience in recruitment from a large patient population, through physician contacts, through support groups contacts, media and educational activities. The Parkinson's Institute has an excellent track record regarding the administrative aspects of clinical trials conduct, including subject safety, confidentiality of information, timely enrollment of subjects, timely completion of study materials and data integrity. These characteristics make the Parkinson's Institute an ideal participant in the proposed trial.

描述（由申请人提供）：该临床中心申请的目的是将帕金森研究所的资格描述为在RFA NS-02-010中提出的针对帕金森氏病神经保护疗法的大型简单试验的参与者。帕金森研究所（Parkinson Institute）具有支持性的研究环境，广泛的临床试验经验和高素质的员工，以及招募临床试验志愿者的经验以及与支持小组的良好关系。研究所的工作人员拥有80多年的临床试验经验，主要研究帕金森氏病的疗法。帕金森研究所通过医师联系，通过支持小组的联系，媒体和教育活动从大量患者人群招募方面拥有丰富的经验。帕金森研究所（Parkinson Institute）在临床试验行为的行政方面，包括主题安全性，信息机密性，及时入学对象，及时完成研究材料和数据完整性。这些特征使帕金森研究所成为拟议试验的理想参与者。